GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Diagnocure Gains Rights to New Prostate Cancer Genes

  • DiagnoCure acquired specific rights and commissioned further research on new genes that show promise as prostate cancer markers. The agreement, signed with Radboud University Medical Center, Nijmegen, the Netherlands, covers technology rights related to Dr. Jack Schalken’s discoveries of the role of FOX gene expression in prostate cancer and commissions further research into the diagnostic, prognostic, and therapeutic potential of those genes.

    “We have sufficient evidence to indicate that specific FOX genes may further enhance the diagnostic efficacy of the PCA3 gene, which in itself reflects a dramatic improvement over PSA testing,” asserts Dr. Schalken.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »